Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Domperidone
PCO Manufacturing Ltd.
A03FA; A03FA03
Domperidone
10 milligram(s)
Film-coated tablet
Product not subject to medical prescription
Propulsives; domperidone
Authorised
2017-10-20
_ _ PACKAGE LEAFLET: INFORMATION FOR THE USER MOTILIUM ® 10 MG FILM COATED TABLETS domperidone READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. Always take this medicine exactly as described in this leaflet or as your doctor or pharmacist have told you. - Keep this leaflet. You may need to read it again. - Ask your pharmacist if you need more information or advice. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. - You must talk to a doctor if you do not feel better or if you feel worse after 7 days. WHAT IS IN THIS LEAFLET 1. What Motilium 10 mg Tablets are and what it is used for 2. What you need to know before you take Motilium 10 mg Tablets 3. How to take Motilium 10 mg Tablets 4. Possible side effects 5. How to store Motilium 10 mg Tablets 6. Contents of the pack and other information 1. WHAT MOTILIUM 10 MG TABLETS ARE AND WHAT IT IS USED FOR This medicine is used to treat nausea (feeling sick) and vomiting (being sick) in adults and adolescents, 12 years of age and older and weighing 35kg or more. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE MOTILIUM 10 MG TABLETS DO NOT TAKE MOTILIUM 10 MG TABLETS IF YOU: are allergic (hypersensitive) to domperidone or any of the other ingredients of Motilium 10 mg Tablets have stomach bleeding or if you regularly have severe abdominal pain or persistent black stools have a blocked or perforated gut have a tumour of the pituitary gland (prolactinoma) have a moderate or severe liver disease have an ECG (electrocardiogram) that shows a heart problem called “prolonged QT interval” have or had a problem where your heart cannot pump the blood around your body as well as it should (condition called heart failure) have a problem that gives you a low level of potassium or magnesium, or a high level of potassium in your blood are taking certain medicines (see “Taking othe Read the complete document
Health Products Regulatory Authority 30 November 2021 CRN00CNVK Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Motilium 10 mg Film-Coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One film-coated tablet contains domperidone 10mg. Excipients with known effect: Each film-coated tablet contains lactose monohydrate. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet _ _ _Product imported from Greece and Austria:_ White to faintly cream-coloured, circular biconvex tablets. 4 CLINICAL PARTICULARS As per PA0330/040/002 5 PHARMACOLOGICAL PROPERTIES As per PA0330/040/002 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS lactose monohydrate maize starch microcrystalline cellulose pregelatinised potato starch povidone magnesium stearate hydrogenated vegetable oil sodium laurilsulfate hypromellose 6.2 INCOMPATIBILITIES Not applicable. 6.3 SHELF LIFE The shelf life expiry date of this product shall be the date shown on the container and outer package of the product on the market in the country of origin. 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 30ºC. Do not refrigerate or freeze. Store in the original package in order to protect from light. Health Products Regulatory Authority 30 November 2021 CRN00CNVK Page 2 of 2 6.5 NATURE AND CONTENTS OF CONTAINER Blister packs containing 10 tablets, packed in a cardboard carton. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL OF A USED MEDICINAL PRODUCT OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCT AND OTHER HANDLING OF THE PRODUCT No special requirements. 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/272/002 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 20 th October 2017 10 DATE OF REVISION OF THE TEXT November 2021 Read the complete document